Comparative Pharmacology
Head-to-head clinical analysis: CIS PYRO versus FERROUS CITRATE FE 59.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CIS PYRO versus FERROUS CITRATE FE 59.
CIS-PYRO vs FERROUS CITRATE FE 59
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cis-pyro is not a recognized pharmaceutical agent. No mechanisms data available.
Ferrous citrate Fe 59 is a radioactive isotope of iron used for diagnostic purposes. It is incorporated into hemoglobin in red blood cells, allowing visualization of erythropoiesis and imaging of the reticuloendothelial system.
Not applicable: CIS-PYRO is a pyrophosphate-based radiopharmaceutical used in cardiac imaging, not a therapeutic drug. Standard adult dose: 555-1110 MBq (15-30 mCi) intravenously once.
Ferrous citrate Fe 59 is a radioactive diagnostic tracer, not a therapeutic iron supplement. Typical adult dose: 2-10 µCi (0.074-0.37 MBq) intravenously as a single dose for iron absorption or red cell utilization studies.
None Documented
None Documented
Terminal elimination half-life: 6-8 hours (IV); prolonged in renal impairment (up to 30 hours in ESRD).
Terminal elimination half-life of Fe-59 from plasma is approximately 1.5-2 hours for free iron, but for total body iron, it is about 5-6 hours initially, followed by a slow phase of 6-10 days due to redistribution to storage sites. Clinically, the long half-life allows imaging of erythropoiesis over days.
Primarily renal excretion: 65-80% unchanged in urine; biliary/fecal excretion accounts for 15-25%.
Fe-59 is primarily excreted via feces (80-90%) as unabsorbed iron, with minor renal excretion (<5%) and negligible biliary elimination. Absorbed iron is incorporated into hemoglobin and red blood cells, with loss via desquamation (~1 mg/day) not reflected in excretion fractions.
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical